Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU GMP Revisions Make Formal Quality Risk Management Plans a Requirement

This article was originally published in The Gold Sheet

Executive Summary

Update on EU GMPs: risk management now required; annexes being updated.

You may also be interested in...



With July 2013 Deadline Looming, Debate Continues Over How to Require GMPs for APIs in Europe

As Europe prepares to subject API imports to GMP controls, industry urges a different approach. Questions linger over how to keep Anti-Falsification Directive from drying up Europe’s API supplies.

FDA and EMA Revising GMP Regulations to Address Supply Chain Deficiencies

FDA, EMA revising GMPs to establish supply chain controls. FDA looks to require identification and auditing of ingredient suppliers, heightened component security, notification of significant defects. EMA to require detailed API supply chain pedigrees and more technical agreements. QPs will have to really vouch for API sites. FDA also plans other GMP changes.

FDA and EMA Revising GMP Regulations to Address Supply Chain Deficiencies

FDA, EMA revising GMPs to establish supply chain controls. FDA looks to require identification and auditing of ingredient suppliers, heightened component security, notification of significant defects. EMA to require detailed API supply chain pedigrees and more technical agreements. QPs will have to really vouch for API sites. FDA also plans other GMP changes.

Latest News
See All
UsernamePublicRestriction

Register

PS000254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel